PitchBook · Jul 2026
PitchBook shows historical funding activity including accelerator/incubator participation, grants, and seed rounds, with a latest deal amount listed at $250K.
XGenomes is building the sequencing technology of the future.
Company research
Public company, workplace, funding, and market signals
Overview
XGenomes is a Cambridge-based biotechnology company developing a next-generation DNA sequencing platform that combines novel biochemistry, hardware, and AI to detect molecular signals of health, disease, and aging. Its mission is to make multi-omic information accessible throughout life, supporting health baselines, early disease detection, and intervention monitoring.
Primary product
OneBox sequencing system / sample-to-sequence platform
Founded
2017
Headquarters
Cambridge, Massachusetts, United States
Team size
1-10
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
DNA sequencing / genomics tools
Offices
The Engine, 750 Main Street, Cambridge, MA 02139, United States
Bioinnovation Centre, Cambridge Science Park, Cambridge, UK
Business model
access-as-a-service
instrument sales
consumables sales
razor-and-blade model
Funding
Stage
Seed
Total raised
$200K
Latest round
Grant · Sep 2019
Latest amount
$200K
People & investors
Leadership
Founder, CEO
Director
Co-founder / Scientist / Consultant
Work & culture
Small, research-heavy team with an in-person, engineering- and science-driven culture focused on sequencing technology development, molecular diagnostics, and AI.
Work style
Onsite
Compensation
No public compensation details were found in the available evidence.
Product & market
Pricing
Initial access-as-a-service offering for high-value customers, then a razor-and-blade model with instruments and consumables; target consumables COGS under $10 and >90% margins.
Differentiators
- —zero library preparation
- —direct sequencing of unadulterated single DNA molecules
- —integrated DNA extraction
- —no bioinformatics bottleneck
- —sequences both strands concurrently
- —high-accuracy output including structural variants, SNVs, haplotype phase, and repetitive regions
- —multi-omic readout
- —sample-to-sequence workflow
Technology
novel biochemistry
hardware
algorithms
super-resolution fluorescence imaging
single-molecule localization microscopy
machine learning
AI-based sequence decoding
epigenetic state decoding
fluorescent oligonucleotide probes
microfluidics / fluidics systems
Python-based control software
Julia
bioinformatics
microscopy tools
Customers
healthcare providers
molecular diagnostics users
precision medicine / personalized healthcare customers
bio-tools / sequencing technology customers
Competitors
Nanopore
PacBio
QuantuMDx
Genoplan
Paragon Genomics
Superbio Biomedical
Dovetail Genomics
Scale & contact
Estimated revenue
Unknown; no reliable public revenue range was found.
Estimated monthly visits
753
Traffic estimate as of Jul 2026
Latest news
SBIR · Sep 2025
XGenomes received a $349,280 NIH SBIR Phase I award to apply deep learning to single-molecule localization microscopy for sequencing and diagnostic assays.
SBIR · Jun 2025
XGenomes received a $397,599 NIH SBIR Phase I award to improve direct reading of DNA methylation and epigenetic modifications.
The Engine · Nov 2024
The Engine describes XGenomes as a resident tough-tech company working to accurately, rapidly, and economically sequence DNA using a sample-to-sequence model.
SBIR · Sep 2024
XGenomes received a $384,418 NIH SBIR Phase I award to develop a super-resolution single-molecule sequencing platform based on oligonucleotide binding kinetics.
Jobs and careers at XGenomes
0 jobs at XGenomes
No open positions
Check back later for new openings